Bayer gets EU approval for Nubeqa for additional indication in prostate cancer Ruchika Sharma5 March 2023 7:30 AM GMTNubeqa is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Venus Remedies bags marketing nod for generic cancer drugs from Uzbekistan, Palestine Ruchika Sharma22 Feb 2023 10:00 AM GMTMumbai: Venus Remedies Limited has received marketing authorisations for its generic cancer drugs from Uzbekistan and Palestine. Having over 800...
Rare case of Serpentine Supravenous Hyperpigmentation reported in NEJM Dr. Kamal Kant Kohli22 Dec 2022 2:30 PM GMTDr Nadine S. Maalouf and Dr Meggie Morand at Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada have reported a rare case of...
Bayer gets USFDA nod for Darolutamide, Docetaxel combo to treat metastatic hormone-sensitive prostate cancer Ruchika Sharma10 Aug 2022 9:30 AM GMTDarolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Drug-makers to add Candidiasis as adverse event in Patient Information Leaflet of anticancer drug Docetaxal: CDSCO Panel Susmita Roy5 Jun 2022 5:30 AM GMTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has recommended that CDSCO may...
Bayer gets USFDA priority review for darolutamide plus docetaxel to treat metastatic hormone-sensitive prostate cancer Ruchika Sharma4 May 2022 6:30 AM GMTDarolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company.
Abiraterone acetate helps with better quality of life than Docetaxel in Prostate Cancer: ASCO Medical Dialogues Editorial Team4 Jan 2022 3:30 AM GMTIn a new research done by Hannah L Rush and colleagues, it was shown that during a 2-year period, patient-reported QOL was superior for patients...
